


# Rheonix™



**FOR IMMEDIATE RELEASE**

## **National Institutes of Health Renews Partnership with Rheonix and Awards Additional Grant to Develop CARD™ Technology for Simultaneous Detection of Multiple Sexually Transmitted Infectious Agents**

**Ithaca, N.Y. — April 16, 2010 —** [Rheonix, Inc.](#) today announced that the [National Institute of Allergy and Infectious Disease \(NIAID\)](#), part of the [National Institutes of Health \(NIH\)](#), continues to support its Point-of-Care Partnership with Rheonix for a second year. As part of the grant, Rheonix will receive an additional \$396,775 award to optimize its [CARD™ \(Chemistry And Reagent Device\)](#) diagnostic platform for simultaneous, multiplex, point-of-care detection of the sexually transmitted infectious (STI) agents that cause gonorrhea, Chlamydia, syphilis, and trichomoniasis. The NIH Partnership is specifically targeted toward underserved and nontraditional health care settings such as rural and urban community public health-care clinics and temporary medical facilities established in response to natural or human-made disasters.

“The extension of this highly-competitive NIH grant continues to validate the strength of our CARD platform in the molecular diagnostics field,” said Tony Eisenhut, Rheonix President and CEO. “The CARD platform offers an unmatched ability to prepare raw samples and perform highly accurate, complex, multiplex analysis in a micro-environment, making Rheonix an ideal partner for aggressive diagnostic efforts, such as the NIH program for underserved communities.”

During the first year of the grant, Rheonix and academic partners at Cornell University successfully developed the CARD’s multiplex capabilities for STI agents of interest and made significant progress toward integration of an electronic biosensor readout into the CARD platform. Based on an evaluation of this progress, the NIH has provided funding for the second year of a possible four year grant.

Richard Montagna, Ph.D., Senior Vice President for Scientific Affairs at Rheonix is the primary principle investigator for the grant and Peng Zhou, Ph.D., Senior Vice President for Research and Development and Chief Scientific Officer at Rheonix and Antje J. Baeumner, Ph.D., Professor of Biotechnology at Cornell University are co-principal investigators for the coordinated effort among Rheonix, Cornell University and the NIAID/NIH.

### **About the CARD™ Diagnostic Platform**

The Rheonix CARD™ (Chemistry And Reagent Device) technology allows sophisticated molecular and/or immunologic assays to be integrated into a simple, modular platform with unprecedented raw sample preparation capabilities and broad, multiplex analysis applications. This technology is extremely versatile and outperforms its labor-intensive

"bench-top" counterparts. Disposable CARDS can be customized for immunoassay, pathogen identification, gene sequence detection, cell based assays and other molecular diagnostic applications. CARD advantages include:

- Virtually no hands-on effort, resulting in significantly reduced labor costs
- Reduced sample volumes and reagent volumes, saving time and money
- Performance of sophisticated assays through a series of programmable, automatic steps
- Integrated biosensors, which enable a highly-sensitive assay with digital readout of results on a completely disposable microfluidic CARD
- Low-cost, scalable, and reproducible manufacturing capabilities

To learn more about the CARD system and its applications, please visit [www.rheonix.com](http://www.rheonix.com).

### **About Rheonix, Inc.**

Rheonix has created a powerful microfluidic platform for the evolving molecular diagnostics industry. Rheonix's system incorporates a low cost disposable CARD™ that analyzes single or multiple clinical raw samples. The CARD provides multiplexed endpoint analysis and can be rapidly customized for a wide breadth of diagnostic applications.

[www.rheonix.com](http://www.rheonix.com)

### **Contacts:**

Rheonix, Inc.  
Tony Eisenhut, President/CEO  
607-257-1242 ext. 160

Media Contact:  
Douglas MacDougall or Jacqui Miller  
MacDougall Biomedical Communications  
781-235-3060